Theravance v. Eugia Pharma: YUPELRI Patent Case Consolidated in 35 Days
Theravance Biopharma R&D IP, LLC filed suit against Eugia Pharma Specialities in the District of New Jersey asserting US12285417B2 covering YUPELRI® revefenacin inhalation solution. Within 35 days, the court ordered the case consolidated into the related lead action No. 1:23-00926-KMW-AMD, streamlining proceedings across both matters.
YUPELRI ANDA Dispute Folded Into Broader Eugia Revefenacin Battle
On May 2, 2025, Theravance Biopharma R&D IP, LLC filed Case No. 1:25-cv-03790 in the U.S. District Court for the District of New Jersey against Eugia Pharma Specialities, Ltd., asserting infringement of US12285417B2. The patent covers YUPELRI® (revefenacin) inhalation solution — a long-acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease — suggesting Eugia had filed an ANDA referencing the branded product.
Just 35 days after filing, on June 6, 2025, the court ordered this case consolidated for all purposes — including discovery, case management, and trial — with the earlier-filed lead action, Case No. 1:23-00926-KMW-AMD. The 3790 Action was administratively terminated and all filings now proceed under the 926 Action caption. Consolidation does not resolve the underlying infringement dispute; it channels the litigation into a single, coordinated track.
The speed of consolidation suggests both parties agreed to the procedural efficiency, consistent with Hatch-Waxman practice where related ANDA cases against the same defendant are routinely merged. The public record of this case does not disclose the specific ANDA details, claim scope contested, or any Paragraph IV certification arguments. Resolution of the patent merits will depend on the amended scheduling order entered in the lead 926 Action.
Filing to Case Consolidated in 35 days
35 days — case resolved into consolidated lead action, faster than typical first-instance ANDA timelines
What case consolidation means for Theravance and Eugia
Consolidation merges cases, not claims — litigation continues
Under Fed. R. Civ. P. 42(a), a court may consolidate actions involving common questions of law or fact. Here, the 3790 Action is administratively terminated, but the infringement claims it contained are absorbed into the lead 926 Action. No judgment on the merits has been issued. Both parties must continue litigating — now under one coordinated schedule.
No merits ruling yetTheravance gains a single, unified litigation track
Consolidation typically benefits the patent holder by reducing duplicative discovery costs and avoiding inconsistent rulings across related ANDA cases. Theravance retains all its infringement assertions under US12285417B2. The 30-month stay triggered by an ANDA filing would continue to run, maintaining market exclusivity for YUPELRI® during proceedings, subject to the lead case schedule.
Exclusivity period preservedEugia faces consolidated discovery and a shared trial track
For Eugia, consolidation means defending its generic revefenacin ANDA position in a single, more intensively managed proceeding. While this reduces duplicative effort, it also means facing a coordinated claim set from Theravance. Eugia’s invalidity and non-infringement arguments, if any, will now be presented on the schedule set in the 926 Action’s forthcoming amended scheduling order.
Single coordinated defenceCOPD inhaler market entry delayed pending consolidated outcome
YUPELRI® is the first once-daily nebulised LAMA approved in the US. Consolidation of ANDA patent litigation signals multiple generic challengers are in play, intensifying competitive pressure on Theravance’s market position. Until the consolidated action resolves or a settlement is reached, Eugia’s generic revefenacin entry remains blocked, preserving Theravance’s branded revenue runway in the COPD maintenance therapy segment.
Generic entry blocked pending trialFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Theravance Biopharma R & D IP, LLC | Company | Search in Eureka ↗ |
| Defendant | Eugia Pharma Specialities, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Theravance Biopharma R & D IP, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a joint agreement between Theravance and Eugia, indicating both parties saw procedural efficiency gains in merging the 3790 Action into the lead 926 matter. The order expressly preserves all merits issues for adjudication in the consolidated proceedings. Administrative termination of this case number does not constitute a dismissal or judgment — it is a docket management mechanism. The substantive infringement and validity questions regarding US12285417B2 remain entirely open and will proceed under an amended scheduling order in the 926 Action.
US12285417B2 — Revefenacin Inhalation Solution for COPD Maintenance
US12285417B2, filed under application No. US18/137922, covers YUPELRI® (revefenacin) inhalation solution — the first and only once-daily nebulised long-acting muscarinic antagonist (LAMA) approved by the FDA for maintenance treatment of chronic obstructive pulmonary disease in adults. Revefenacin’s mechanism involves selective M3 muscarinic receptor antagonism in the airways, delivered via standard jet nebuliser. The patent’s application date context suggests it is a later continuation within Theravance’s revefenacin patent family, potentially covering formulation, method of use, or dosing innovations.
For the COPD maintenance market, YUPELRI® occupies a distinct niche as a nebulised alternative to dry-powder and MDI LAMAs, serving patients unable to use handheld inhalers. This makes the patent strategically significant: generic entry would directly address an underserved patient segment and a growing revenue stream for Theravance. With multiple ANDA filers now consolidated into one proceeding, the outcome of the 926 Action will set the definitive validity and infringement precedent for the entire revefenacin generic entry race.
Should you run an FTO against US12285417B2?
Any company developing, formulating, or seeking to commercialise a generic or biosimilar nebulised revefenacin inhalation solution in the US should conduct a freedom-to-operate analysis against US12285417B2 before advancing an ANDA filing. The consolidated litigation confirms the patent is actively enforced. Companies in adjacent LAMA or nebulised bronchodilator programs should also assess whether their formulation or delivery mechanism falls within the patent’s claim scope.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US12285417B2 against your product specifications, identify the continuation chain and family members, and flag co-pending applications that could mature into additional blocking IP. For COPD inhaler R&D teams, Eureka can also surface the full Theravance revefenacin portfolio to reveal the scope of exclusivity you need to design around before committing to manufacturing investment.
Run a freedom-to-operate analysis on US12285417B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: Inhaled COPD Therapies in New Jersey District Court
Cases involving nebulised and inhaled COPD therapy ANDA disputes litigated in the District of New Jersey, where Hatch-Waxman patent consolidations are frequently managed.
What this consolidation signals for the COPD inhaler IP landscape
Multiple ANDA filers targeting YUPELRI® suggest Theravance’s revefenacin exclusivity is under coordinated pressure from generic manufacturers.
Hatch-Waxman consolidations signal a crowded ANDA field
When a brand holder files successive ANDA suits against the same generic challenger that get consolidated, it typically signals overlapping patent families or multiple manufacturing entities under one corporate group. Companies monitoring the COPD inhaler space should track the 926 lead action docket for scheduling orders that will define the trial timeline.
US12285417B2 is now the key patent to watch in revefenacin ANDA disputes
Consolidation into a single case means claim construction and validity rulings on US12285417B2 will apply across all consolidated defendants. Any adverse finding on this patent — invalidity, non-infringement — would have immediate commercial consequences for Theravance’s YUPELRI® exclusivity across all ANDA challengers simultaneously.
Theravance v Eugia — key questions answered
Consolidation means Case No. 1:25-cv-03790 has been merged into lead action 1:23-00926-KMW-AMD for all purposes including discovery and trial. The 3790 case is administratively terminated but no merits ruling has been issued. All infringement claims regarding US12285417B2 continue in the lead case.
The asserted patent is US12285417B2 (application No. US18/137922), which covers YUPELRI® (revefenacin) inhalation solution — a once-daily nebulised long-acting muscarinic antagonist for COPD maintenance treatment in adults. It is the first once-daily nebulised LAMA approved by the FDA.
No. The June 6, 2025 order solely consolidates this action into the lead case. Administrative termination of Case No. 1:25-cv-03790 is a docket management measure. Infringement and validity questions under US12285417B2 remain open and will be adjudicated in the consolidated 926 Action proceedings.
The lead case is No. 1:23-00926-KMW-AMD, also filed in the U.S. District Court for the District of New Jersey. All future filings in the consolidated actions use the 926 Action caption and are filed in that docket. An amended scheduling order reflecting the parties’ agreed timeline is forthcoming in that lead matter.
Consolidation itself does not terminate or modify the 30-month stay. The stay, triggered by Theravance’s timely suit in response to Eugia’s ANDA Paragraph IV certification, continues to run according to its original trigger date. The consolidated proceedings would need to conclude — or the stay expire — before Eugia could lawfully launch a generic revefenacin product, absent a court order lifting the stay.
PatSnap Eureka searches patents and litigation data to answer instantly.